Vaccine Updates

1/26/22

Primary COVID-19 Vaccination Recommended for Everyone 5 Years and Older

TABLE 1. COVID-19 vaccines: primary series and additional primary dose

Vaccine manufacturer	Age indication	Vial cap color denoting formulation	Dose	Injection volume	Number of doses in primary series (interval between doses)	Additional primary dose in immunocompromised people (interval since second dose)
Pfizer-BioNTech	5–11 years	Orange	10 µg	0.2 mL	2 (21 days)	1 (≥28 days)
Pfizer-BioNTech	≥12 years	Purple or gray	30 µg	0.3 mL	2 (21 days)	1 (≥28 days)
Moderna	≥18 years	Not applicable	100 µg	0.5 mL	2 (28 days)	1 (≥28 days)
Janssen	≥18 years	Not applicable	5×10^{10} viral particles	0.5 mL	1 (Not applicable)	Not applicable

Boosters Recommended for 12+ years old and 5 months after primary mRNA series

TABLE 2. COVID-19 vaccines: booster dose by primary series

Vaccine completed for primary series	Authorized age for vaccine booster	Interval between last primary dose (including additional dose, when applicable) and booster dose	Number of doses	Injection volume and product that may be given as booster dose*†
Pfizer-BioNTech	≥12 years	≥5 months	1	0.3 mL Pfizer-BioNTech*, or 0.25 mL Moderna, or 0.5 mL Janssen†
Moderna	≥18 years	≥5 months	1	0.25 mL Moderna, or 0.3 mL Pfizer-BioNTech, or 0.5 mL Janssen†
Janssen	≥18 years	≥2 months	1	0.5 mL Janssen†, or 0.3 mL Pfizer-BioNTech, or 0.25 mL Moderna

Boosters Continue to Protect Nursing Home Residents

Unadjusted COVID-19 Cases Per 1,000 Nursing Home Residents, by COVID-19 Vaccination Status (Including Additional Primary and Booster Doses) and Week, United States



Data source: Centers for Disease Control and Prevention, National Healthcare Safety Network
For more information: https://www.cdc.gov/nhsn/ltc/weekly-covid-vac/index.html
Note: Data reported in the most recent week may still be accruing.

Data as of 01/17/2022 05:30 AM

MMWR: Effectiveness of Third mRNA Dose against COVID-19-Associated ED/UC Visits and Hospitalizations

- CDC Morbidity and Mortality Weekly Report (MMWR)
- VISION Network sites across 10 states, includes Kaiser Northern California
- 222,772 encounters from
  - 383 emergency departments (EDs) and urgent care (UC) clinics
  - 87,904 hospitalizations from 259 hospitals
- Adults aged ≥18 years
- August 26, 2021 to January 5, 2022 during
  - periods of Delta predominance and
  - Omicron variant predominance
- Test-negative design
  - Comparing vaccinated and
  - Unvaccinated patients and
  - Odds of having a positive SARS-CoV-2 molecular test result

Vaccine Effectiveness of 3rd mRNA Dose against COVID-19-associated Hospitalizations during Delta and Omicron

TABLE 2. mRNA COVID-19 vaccine effectiveness* against laboratory-confirmed COVID-19–associated† emergency department and urgent care encounters and hospitalizations among adults aged ≥18 years, by number and timing of vaccine doses§ and vaccine product received — VISION Network, 10 states, August 2021–January 2022¶

Encounter/Predominant variant period/Vaccination status	Total	SARS-CoV-2 positive test result, no. (%)	VE, %* (95% CI)
Hospitalizations			
Delta predominant			
Unvaccinated (Ref)	**37,400**	14,272 (38.2)	—
Any mRNA vaccine			
2 doses (14–179 days earlier)	**14,645**	895 (6.1)	90 (89–90)
2 doses (≥180 days earlier)	**26,190**	2,563 (9.8)	81 (80–82)
3 doses	**8,092**	209 (2.6)	94 (93–95)
Omicron predominant			
Unvaccinated (Ref)	**460**	174 (37.8)	—
Any mRNA vaccine			
2 doses (14–179 days earlier)	**115**	14 (12.2)	81 (65–90)
2 doses (≥180 days earlier)	**488**	86 (17.6)	57 (39–70)
3 doses	**514**	24 (4.7)	90 (80–94)

MMWR (1/21/22): Effectiveness of Third Dose of mRNA Against COVID-19-Associated Emergency Dept and Urgent Care Encounters and Hospitalizations

MMWR: COVID-19 Incidence and Death Rates among Unvaccinated and Fully Vaccinated Adults with and without Boosters during Delta and Omicron

- CDC Morbidity and Mortality Weekly Report (MMWR)
- 25 state and local health departments, includes California
- 6,812,040 COVID-19 cases
- 11,047 associated deaths
- Adults aged ≥18 years
- April to December 2021 during
  - periods of Delta predominance and
  - Omicron variant predominance
- Incidence Rate Ratios calculated by dividing incidence among unvaccinated persons by incidence among fully vaccinated persons (overall and by receipt of booster doses)

MMWR (1/21/22): COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence

Boosters Protect against COVID-19 Infections and COVID-19-associated Deaths

FIGURE. Weekly trends in age-standardized incidence of COVID-19 cases (April 4–December 25, 2021) and deaths (April 4–December 4, 2021) for unvaccinated compared with fully vaccinated persons,* overall and by receipt of booster doses† and national weighted estimates of variant proportions§ — 25 U.S. jurisdictions¶



MMWR (1/21/22): COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence

Boosters Protect against COVID-19 Infections during Omicron

TABLE 2. Average weekly incidence* of cases and deaths and incidence rate ratios† for unvaccinated compared with fully vaccinated persons§ with and without booster doses,¶ by age, vaccine type, and period†† — 25 U.S. jurisdictions§§ October 3–December 25, 2021**

	COVID-19 vaccination status							
	Unvaccinated		Fully vaccinated (no booster dose)			Fully vaccinated (with booster dose)		
Event/Time/ Characteristic	Total no.	Average weekly incidence*	Total no.	Average weekly incidence*	Average weekly IRR (95% CI)¶¶	Total no.	Average weekly incidence*	Average weekly IRR (95% CI)¶¶
COVID-19 Cases (December)								
Overall (age-standardized)	1,061,684	725.6	800,940	254.8	2.8 (1.6–5.2)	125,059	148.6	4.9 (2.7–8.9)
Age group, yrs								
18–49	781,969	745.6	547,733	302.5	2.5 (1.1–5.6)	65,710	191.7	3.9 (1.8–8.6)
50–64	189,789	680.8	176,639	208.8	3.3 (1.7–6.4)	31,753	97.0	7.0 (3.0–16.3)
≥65	89,926	704.9	76,568	133.5	5.3 (3.3–8.4)	27,596	50.4	14.0 (6.4–30.6)
Vaccine								
Moderna	NR	NR	251,784	221.6	3.3 (1.7–6.1)	39,813	130.4	5.6 (3.1–10.1)
Pfizer-BioNTech	NR	NR	473,115	280.1	2.6 (1.4–4.7)	77,844	162.6	4.5 (2.4–8.3)
Janssen (Johnson & Johnson)	NR	NR	75,903	246.6	2.9 (1.8–4.8)	7,377	132.7	5.5 (3.2–9.4)

MMWR (1/21/22): COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence



MMWR (1/21/22): COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence

UPDATED

Job Aids: COVID-19 Vaccine Eligibility Chart & Guidance for COVID-19 Vaccine Eligibility

Includes recent recommendations for:

- Additional dose in immunocompromised 5-to-11-year-olds
- Booster dose in 12-to-15-year-olds
- Booster dose at 5 months after primary series of Pfizer for those 12-years-and -older



COVID-19 Vaccine Eligibility

Vaccinate ALL 58

Use this chart to help determine when to give COVID-19 vaccine based on age or health conditions.

	Dose	Age: 5-11	12-17	18+
Pfizer–Pediatric (5-11)	**Primary 2 doses** (21 days apart)	✓		
	Additional (3rd) dose for immunocompromised, at least 28 days after 2nd Pfizer dose	✓		
Pfizer/ Comirnaty (12+)	**Primary 2 doses** (21 days apart)		✓	✓
	Additional (3rd) dose for immunocompromised, at least 28 days after 2nd Pfizer dose		✓	✓
	Booster dose* of Pfizer (or Moderna if age 18+), at least **5** months after 2nd dose of Pfizer		✓	✓
Moderna (18+)	**Primary 2 doses** (28 days apart)			✓
	Additional (3rd) dose for immunocompromised, at least 28 days after 2nd Moderna dose			✓
	Booster dose* of Moderna **(half-dose)** or Pfizer, at least 6 months after 2nd dose of Moderna			✓
Johnson & Johnson (18+) Use of Pfizer or Moderna is preferred.*	**Primary 1 dose**			✓
	Booster dose* of different brand (preferred) or J&J, at least 2 months after primary J&J dose			✓

* Use of mRNA COVID-19 vaccines is preferred over the Janssen COVID-19 vaccine. However, the Janssen vaccine may be offered in some situations:

- When there is a contraindication to mRNA COVID-19 vaccines (e.g., severe allergic reaction after a previous dose or to a component of an mRNA COVID-19 vaccine)
- When a person would otherwise remain unvaccinated due to limited access to mRNA COVID-19 vaccines
- When a person wants to receive the Janssen COVID-19 Vaccine despite the safety concerns identified

View Related Guidance and Requirements. (Eligibility is subject to change as guidance is updated.)

California COVID-19 Vaccination Program IMM-1396 (1/5/22)



Guidance for COVID-19 Vaccine Eligibility

Vaccinate ALL 58

California COVID-19 Vaccination Program

Refer to these additional resources for specific eligibility criteria listed in the COVID19 Vaccine Eligibility chart. Information is subject to change as guidance is updated.

Primary Series for Ages 5+

COVID-19 vaccination is recommended for everyone aged 5 years and older.

- Preferential Recommendation for mRNA COVID-19 Vaccines (WSSSRW)
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States (CDC)
- Guidance for Vaccination During Pregnancy (CDPH)
- COVID-19 Vaccines While Pregnant or Breastfeeding (CDC)
- Considerations for Vaccination of People with Certain Underlying Medical Conditions (CDC)
- Requirement that COVID-19 immunization providers request patients' email addresses and mobile phone numbers for the State's Immunization Registry (State Public Health Officer Order, CDPH)

State Public Health Officer Orders and Requirements for Work or Institutional Settings:

- Adult Care Facilities and Direct Care Worker Vaccine Requirement (State Public Health Officer Order, CDPH)
- Requirements for Visitors in Acute Health Care and Long-Term Care Settings (State Public Health Officer Order, CDPH)
- State and Local Correctional Facilities and Detention Centers Health Care Worker Vaccination Requirement (State Public Health Officer Order, CDPH)
- Vaccine Verification for Workers in Schools (State Public Health Officer Order, CDPH)
- Upcoming Requirements for School (Governor's Announcement)
- Health Care Worker Vaccine Requirement (State Public Health Officer Order, CDPH)
- Cruise Ship Operators: Minimum Recommended Standards for Local Agreements under CDC's Conditional Sailing Order (CDPH)
- Revisions to the COVID-19 Prevention Emergency Temporary Standards (Cal/OSHA)

California COVID-19 Vaccination Program IMM-1398 (1/7/2022)

CDC: COVID-19 Vaccines for Long-term Care Residents

Centers for Disease Control and Prevention
CDC 24/7: Saving Lives, Protecting People™

Search COVID-19

COVID-19

Your Health | Vaccines | Cases & Data | Work & School | Healthcare Workers | Health Depts | Science | More

Vaccines

- Your Vaccination
  - Find a Vaccine
  - Preparing for Your Vaccine
  - Specific Groups of People
    - COVID-19 Vaccines for Long-term Care Residents
  - When Getting Your Vaccine

COVID-19 Vaccines for Long-term Care Residents

Updated Jan. 21, 2022 Languages Print

Residents of long-term care (LTC) settings ages 5 years and older are recommended to get vaccinated against COVID-19.

There are many examples of long-term care (LTC) settings.

Many LTC settings, such as residential care, assisted living, nursing homes, and continuing care retirement communities provide care to older adults with underlying medical conditions, often living closely together. These medical conditions and living situations can make residents more likely to be infected by the virus that causes COVID-19 and to become seriously ill from COVID-19.